[ad_1]
On the subject of vaccination in people with basic diseases, a group of people who are expected to have priority in access to the vaccine, after health, mentions in a new post the professor of health policy of the LSE, Elias Mosialos.
Specifically, Mr. Mosialos says that many wonder about the priority groups in vaccinations, but also about the special characteristics of those who can be excluded. “The available data, however, does not indicate a concern about the safety or side effects of the vaccines,” he said.
“I have already referred to the UK vaccination guidelines for pregnant women and children under 12 years of age. Since pregnant women and young children were not included in clinical trials, there is no scientific knowledge or evidence of a risk of vaccination during pregnancy.
After infection with the new coronavirus, almost all children have an asymptomatic infection or mild illness. There are very limited data on vaccination in adolescents and we do not have data on vaccination in younger children. “For 12-18 year olds, there are ongoing clinical trials and we will have safety and efficacy data soon.”
The following are guidelines for pregnant women in the UK:
- Postpone vaccination until the pregnancy is complete.
- If a woman discovers she is pregnant after taking the first dose to complete her pregnancy before taking the second dose.
- New mothers who breastfeed can be vaccinated.
- Pregnant women who are considered to be in a high risk group, due to other health factors, should be vaccinated as soon as possible after the end of the pregnancy.
For what other years and not illnesses do we have data from the advertisements of the clinical trial companies?
As for the elderly, as announced by Pfizer / BioNTech, the efficiency in adults over 65 years was higher than 94%, he emphasizes.
“In early September, Pfizer / BioNTech announced that they had requested an extension of the phase II / III clinical trial – from 30,000 to 44,000 participants – to the FDA, because they had many volunteers who wanted to participate. This expansion has allowed companies to include adolescents up to 16 years old and people with chronic but stable HIV (the human immunodeficiency virus that causes AIDS), hepatitis C or hepatitis B. So we know that among these 14,000 additional volunteers there are and some adolescents 16-18 years and patients with the mentioned diseases We will await the scientific publications for the in-depth analysis and more details.
The Moderna Phase III clinical trial, according to the company, also included groups of citizens at high risk of serious complications from COVID-19. We know that the study included more than 7,000 Americans older than 65 and more than 5,000 Americans younger than 65 but with chronic conditions.
These vulnerable volunteers made up 42% of the participants in the phase III study (about 15% had diabetes, 10.5% had severe obesity, about 8% had severe heart disease, about 7.6% had pneumonia severe and nearly 1% liver disease). The safety data and the effectiveness of the vaccine have been verified and, as I mentioned before, we will await the scientific publications for more details.
“We now know that some underlying health conditions increase the risk of morbidity and mortality from COVID-19.”
Then he refers to the UK, which is preparing for vaccines. As you point out, the committee’s advice on priority groups has already been announced. Among them are people aged 65 and over with no underlying diseases, followed by people in high-risk groups aged 16 and over.
The risk groups identified by the committee are listed below:
- Chronic respiratory disease, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and severe asthma.
- chronic heart disease (and vascular disease)
- chronic kidney disease
- chronic liver disease
- chronic neurological disease including epilepsy
- Down’s Syndrome
- severe learning disability
- diabetes
- solid, bone marrow and stem cell transplant recipients
- some cancer patients
- immunosuppression due to disease or treatment
- asplenia and splenic dysfunction
- severe obesity
- severe mental illness
At the same time, he explains that we expect further clarification on these allegations in the coming weeks.
Finally, he concludes that “all countries are preparing for the next vaccinations and it is expected that very soon we will have more details about the relative risk between the previous ones, but also other groups with chronic diseases. I am referring to relevant scientific publications resulting from analyzes of groups of patients with other diseases that are not listed above. At the moment, the decisions of the European Medicines Agency for the first two vaccines are a priority. “
See the post of Mr. Mosialos
Vaccination and people with underlying diseases.
Pending approval of vaccines from the European Agency …
Posted by Elias Mosialos on Sunday, December 6, 2020
at google news and be the first to know all the news
[ad_2]
